NICE Rejects Shire’s Pancreatic Cancer Drug

Shire's Onivyde has been turned down by NICE as an NHS-funded treatment for pancreatic cancer.

The drug was cleared for use in Europe to treat metastatic adenocarcinoma of the pancreas.

NICE has issued draft guidance rejecting the drug after concluding that it does not fall within the range of what is normally considered cost effective for routine NHS use.

They agreed that the criterion for short life expectancy was met, but that end-of-life weighting could not be applied because criterion for extension to life was not met for the comparison.